| Range |
~15-20 %
|
| Organism |
Mammals |
| Reference |
Koivuniemi A. The biophysical properties of plasmalogens originating from their unique molecular architecture. FEBS Lett. 2017 Sep591(18):2700-2713. doi: 10.1002/1873-3468.12754 p.2701 right column 2nd paragraphPubMed ID28710769
|
| Primary Source |
[9] Braverman NE, Moser AB. Functions of plasmalogen lipids in health and disease. Biochim Biophys Acta. 2012 Sep1822(9):1442-52. doi: 10.1016/j.bbadis.2012.05.008 [14] Han X, Holtzman DM, McKeel DW Jr. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem. 2001 May77(4):1168-80PubMed ID22627108, 11359882
|
| Method |
Primary source [14] abstract: "To explore the hypothesis that alterations in ethanolamine plasmalogen may be directly related to the severity of dementia in Alzheimer's disease (AD), [investigators] performed a systematic examination of plasmalogen content in cellular membranes of gray and white matter from different regions of human subjects with a spectrum of AD clinical dementia ratings (CDR) using electrospray ionization mass spectrometry (ESI/MS)." |
| Comments |
P.2701 right column 2nd paragraph: "Plasmalogens are present almost in all mammalian tissues and their average percentage is approximately 15–20% of total phospholipids [primary sources]. Consequently, plasmalogens can be treated as a major phospholipid component of cell membranes. They are mostly enriched in the brain, heart, skeletal muscle and kidney, the most abundant plasmalogens being ethanolamine plasmalogens (PlsPEs) and choline plasmalogens (PlsPCs) [refs 12, 15]." |
| Entered by |
Uri M |
| ID |
114191 |